The growth of the acute ischemic stroke market is expected to be driven primarily by increased awareness of symptoms, advances in acute stroke care, and a robust pipeline of potential candidates such ...

Company to Highlight Imaging Biomarkers for Cytoprotection and Post Hoc Analysis from Phase 2 RESCUE Clinical Trial; RNS60 Led to Shorter Hospital Stays in Acute Ischemic Stroke Subjects Enrolled with ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.

Older adults with Medicare Advantage plans, particularly those also eligible for Medicaid, are less likely to access skilled nursing.

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Current guidelines restrict intravenous thrombolysis to a short window after stroke onset. Advances in perfusion imaging, however, now allow identification of patients with salvageable brain tissue ...

Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...

Antidepressant therapy may independently improve recovery from dysphagia after acute ischemic stroke through multiple ...

For acute ischemic stroke within 48 hours of onset, the novel sublingual combination of edaravone (Radicava) with dexborneol appeared to dramatically improve functional outcomes in the phase III TASTE ...

Patients with pulmonary adenocarcinoma consulted the neurology department due to multiple initial symptoms of cerebral ischaemia. Examination of each patient revealed pulmonary embolism, the ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a single ...